IRIDEX (IRIX) Stock Overview
An ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IRIX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
IRIDEX Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$1.65 |
| 52 Week Low | US$0.87 |
| Beta | 0.64 |
| 1 Month Change | -2.65% |
| 3 Month Change | 10.01% |
| 1 Year Change | 8.91% |
| 3 Year Change | -45.00% |
| 5 Year Change | -82.51% |
| Change since IPO | -89.27% |
Recent News & Updates
Recent updates
Growing Laser Glaucoma Adoption And Cost Restructuring Will Support A Stronger Long Term Outlook
Catalysts About IRIDEX IRIDEX develops and sells ophthalmic laser systems and related disposable products for glaucoma and retina procedures worldwide. What are the underlying business or industry changes driving this perspective?Revenues Working Against IRIDEX Corporation's (NASDAQ:IRIX) Share Price Following 26% Dive
IRIDEX Corporation ( NASDAQ:IRIX ) shareholders won't be pleased to see that the share price has had a very rough...Is IRIDEX (NASDAQ:IRIX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Iridex's Strategic Review Process Should Bear Fruit 'Soon'
Summary Iridex Corporation is undergoing a strategic review process to unlock shareholder value. The company is likely to sell its retina business line and potentially parse it out in more than one transaction "soon." The glaucoma business line is highly promising but likely needs to be in the hands of a bigger company to reach its full potential. The entire business may be worth double the current share prices, in line with what Topcon paid three years ago to acquire a 10% stake. Read the full article on Seeking AlphaLittle Excitement Around IRIDEX Corporation's (NASDAQ:IRIX) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.7x IRIDEX Corporation ( NASDAQ:IRIX ) is definitely a...Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Lacklustre Performance Is Driving IRIDEX Corporation's (NASDAQ:IRIX) 32% Price Drop
IRIDEX Corporation ( NASDAQ:IRIX ) shareholders that were waiting for something to happen have been dealt a blow with a...Will IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Hopeful That IRIDEX (NASDAQ:IRIX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is IRIDEX (NASDAQ:IRIX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Shareholder Returns
| IRIX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.7% | -1.3% | 0.7% |
| 1Y | 8.9% | -18.6% | 20.6% |
Return vs Industry: IRIX exceeded the US Medical Equipment industry which returned -19.9% over the past year.
Return vs Market: IRIX underperformed the US Market which returned 19.5% over the past year.
Price Volatility
| IRIX volatility | |
|---|---|
| IRIX Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IRIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IRIX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 93 | Patrick Mercer | www.iridex.com |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
IRIDEX Corporation Fundamentals Summary
| IRIX fundamental statistics | |
|---|---|
| Market cap | US$19.50m |
| Earnings (TTM) | -US$3.27m |
| Revenue (TTM) | US$52.58m |
Is IRIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRIX income statement (TTM) | |
|---|---|
| Revenue | US$52.58m |
| Cost of Revenue | US$33.67m |
| Gross Profit | US$18.91m |
| Other Expenses | US$22.19m |
| Earnings | -US$3.27m |
Last Reported Earnings
Apr 04, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 35.97% |
| Net Profit Margin | -6.23% |
| Debt/Equity Ratio | 79.6% |
How did IRIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 18:16 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/04/04 |
| Annual Earnings | 2026/01/03 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IRIDEX Corporation is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Scott Henry | Roth Capital Partners |
| Joseph Munda | Sidoti & Company, LLC |